Fondaparinux for the Treatment of Superficial-Vein Thrombosis in the Legs

Risk of venous and arterial thrombotic events in patients diagnosed with superficial vein thrombosis: a nationwide cohort study

“…Having been considered a benign and self-limiting disease, not normally needing treatment, several large studies have shown that the risk of concomitant or subsequent DVT or PE is substantial, and that anticoagulant treatment is beneficial in preventing progression to a more serious thromboembolic event. 4,6,9 In our study, we focused on isolated SVT, excluding concomitant DVT or PE, and examined immediate and longer-term VTE risk during a period when SVT was not treated with anticoagulant therapy. Our findings suggest 2 conclusions about the relation between superficial and deep venous events.…”

“…7,8 This close association between SVT and DVT/PE prompted the Comparison of Arixtra in Lower Limb Superficial Vein Thrombosis with Placebo (CALISTO) trial, which showed that a 45-day anticoagulant treatment regimen after SVT is effective and safe in preventing serious thrombotic events in the 3 months after diagnosis. 9 Two other trials have confirmed these findings. 10,11 As a result, current guidelines now recommend this treatment regimen for patients with SVT of at least 5 cm in length on a lower limb.…”

Massive Pulmonary Embolism Following Varicose Vein Surgery That Was Successfully Treated with Thrombolytic Therapy

“…In fact, patients treated with a much cheaper oral nonsteroidal antiinflammatory agent eventually showed identical results. In the 2010 Calisto Study, antithrombotic prophylaxis was extended to 45 days and a clear advantage was demonstrated (10). However, it remains unclear in regard to the optimal timing to initiate prophylactic anticoagulants following varicose vein operation, and recent guidelines do not recommend prophylaxis with anticoagulants in this setting (11).…”

The negative predictive value of D‐dimer on the risk of recurrent venous thromboembolism in patients with multiple previous events: A prospective cohort study (the PROLONG PLUS study)

“…A recurrent DVT was diagnosed if a previously fully compressible segment (contralateral or ipsilateral) was no longer compressible or if an increase of at least 4 mm in the diameter of the residual thrombus during compression was detected [13]. A recurrent superficial vein thrombosis was diagnosed in the presence of extension, defined as proximal progression of the initial thrombus by at least 2 cm and to within 3 cm or less from the sapheno-femoral junction, or in the presence of a new thrombus located in a different superficial vein and not directly contiguous upstream with the index thrombus, or located in the same superficial vein, but separated from the index thrombus by at least 10 cm [14]. In patients with suspected PE, the diagnosis of recurrence was based on the use of clinical probability, perfusion lung scanning or helical CT, and compression ultrasonography, D-dimer testing, or both if indicated [15].…”